Ozempic for weight loss? Know the risks of off-label prescriptions
Ozempic (semaglutide) is a prescription drug approved to treat type 2 diabetes that has become one of the most in-demand medications in North America in recent years. Demand for Ozempic, which is manufactured by Novo Nordisk, has driven shortages in the United States. Health Canada observed …
View the post titled Ozempic for weight loss? Know the risks of off-label prescriptionsBladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 report
Elmiron, a medication prescribed for bladder issues that has been linked to a unique form of macular degeneration causing vision loss, continues to rank among the top publicly funded non-patented drugs in Canada, according to a government report on public drug plan expenditures published ear…
View the post titled Bladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 reportOntario Court of Appeal decides non-party litigation funders not liable for defendants’ costs in Davies v. Clarington (Municipality)
In Davies v. Clarington (Municipality), 2023 ONCA 376, the Ontario Court of Appeal reached the reasonable conclusion that non-party lenders with no involvement in directing litigation are not liable to pay an adverse costs award that a plaintiff will not pay. On this appeal, the Court provi…
View the post titled Ontario Court of Appeal decides non-party litigation funders not liable for defendants’ costs in Davies v. Clarington (Municipality)Xeljanz, linked to heart attacks, blood clots, and cancers – is now approved to treat arthritis of the spine
Xeljanz, an arthritis drug that has been the subject of multiple Health Canada advisories due to its potential to expose users to serious health risks (including heart attack, cancer, and death), has now been approved for use to treat a new type of chronic health condition: ankylosing spondy…
View the post titled Xeljanz, linked to heart attacks, blood clots, and cancers – is now approved to treat arthritis of the spineCanopy Growth Corporation’s alleged misrepresentation of BioSteel’s revenue (TSX: WEED; NASDAQ: CGC)
On July 6, 2023, Siskinds LLP filed a proposed securities misrepresentation class action in the Ontario Superior Court of Justice against Canopy Growth Corporation, its directors and senior officers, Canopy’s auditor KPMG LLP and two of BioSteel Sports Nutrition Inc.’s (“BioSteel”) senior of…
View the post titled Canopy Growth Corporation’s alleged misrepresentation of BioSteel’s revenue (TSX: WEED; NASDAQ: CGC)Newly released J&J bankruptcy plan for compensating talcum powder cancer claims includes Canadian claims
A Johnson & Johnson subsidiary that is pursuing a US bankruptcy to resolve thousands of talcum powder lawsuits has filed its plan for compensating cancer victims with pending claims, and the proposed plan directly impacts the rights of Canadians. The Chapter 11 Plan of Reorganization pr…
View the post titled Newly released J&J bankruptcy plan for compensating talcum powder cancer claims includes Canadian claimsInstitutional abuse litigation
Throughout Canada, recent years have seen repeated discoveries of abuse in institutional settings. Allegations against religious organizations, educational facilities, nursing homes, and correctional facilities have brought to light horrific stories of the mistreatment, neglect and abuse of …
View the post titled Institutional abuse litigationCanadians can now claim under $20 million OxyContin class actions settlement
On May 27, 2023, a claims filing process becomes open to Canadians to apply for compensation for injuries suffered from addictions to OxyContin and OxyNEO. The claims process gives Canadian opioid victims the chance to receive funds from a $20 million Settlement to resolve longstanding Oxy…
View the post titled Canadians can now claim under $20 million OxyContin class actions settlementSame as it ever was? Divisional Court sets out Ontario law on honoraria in Doucet et al. v The Royal Winnipeg Ballet et al.
In March of 2022, we blogged about honoraria and observed that while Ontario was trending towards a more permissive approach where such payments are commonly approved, Justice Perell’s decision in Doucet v The Royal Winnipeg Ballet, 2022 ONSC 976 (“Doucet”),was an outlier that took Ontario l…
View the post titled Same as it ever was? Divisional Court sets out Ontario law on honoraria in Doucet et al. v The Royal Winnipeg Ballet et al.Canadian Invokana / Invokamet Settlement now open to claims
On April 15, 2023, a claims filing process became open to Canadians to apply for compensation for injuries suffered following use of the diabetes medications Invokana, Invokamet and/or Invokamet XR. The claims process will give Canadians the chance to apply to have their claims evaluated pur…
View the post titled Canadian Invokana / Invokamet Settlement now open to claimsReceive Blog Posts
By subscribing to our blog, you will receive an email when a new post is added. You can unsubscribe at any time by sending an email to us at [email protected] with the word “unsubscribe” in the subject line.